Imunon (NASDAQ:IMNN) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Imunon (NASDAQ:IMNN) in a report issued on Monday,Benzinga reports. The firm currently has a $29.00 price target on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Imunon in a report on Thursday, December 19th.

Imunon Stock Up 12.1 %

Shares of NASDAQ:IMNN opened at $1.07 on Monday. Imunon has a fifty-two week low of $0.64 and a fifty-two week high of $3.65. The firm’s 50 day moving average price is $0.90 and its 200 day moving average price is $0.92. The stock has a market cap of $15.57 million, a price-to-earnings ratio of -0.56 and a beta of 1.96.

Institutional Investors Weigh In On Imunon

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC boosted its stake in Imunon, Inc. (NASDAQ:IMNN) by 10.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 139,505 shares of the company’s stock after acquiring an additional 13,570 shares during the period. Geode Capital Management LLC owned 0.96% of Imunon worth $133,000 as of its most recent SEC filing. 4.47% of the stock is currently owned by institutional investors and hedge funds.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.